Brief: Alteogen receives China patent
17/07/2018 05:39
July 17 (Reuters) - Alteogen Inc 196170.KQ :
* Says it receives China patent on July 17, for modified
antibody
in which motif comprising cysteine residue is bound, modified
antibody-drug conjugate comprising the modified antibody, and
production method for same
Source text in Korean : https://goo.gl/2i2WfP
Further company coverage: 196170.KQ
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: hedy.cui.reuters.com@reuters.net))
Recent news on Alteogen
See all newsBrief: Alteogen Enters Into A License Agreement With Biogen For Development And Commercialization Of Hybrozyme™-Based Subcutaneous Biologics
Brief: Alteogen Signs Licensing Deal With Biogen International For Alt-B4
Brief: Alteogen 2025 Operating Profit 115 Billion Won, Up 275% From Year Earlier
Brief: Alteogen Signs $285 Million Contract With Gsk Unit
Brief: Alteogen Receives Positive CHMP Opinion For Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'